STERIS 과거 순이익 실적
과거 기준 점검 5/6
STERIS은 연평균 21.6%의 비율로 수입이 증가해 온 반면, Medical Equipment 산업은 수입이 14.8% 증가했습니다. 매출은 연평균 9.7%의 비율로 증가했습니다. STERIS의 자기자본이익률은 10.9%이고 순이익률은 13.2%입니다.
핵심 정보
21.61%
순이익 성장률
20.18%
주당순이익(EPS) 성장률
| Medical Equipment 산업 성장률 | 8.90% |
| 매출 성장률 | 9.66% |
| 자기자본이익률 | 10.91% |
| 순이익률 | 13.18% |
| 다음 순이익 업데이트 | 05 Aug 2026 |
최근 과거 실적 업데이트
Recent updates
Seeking Alpha • Jul 27
Steris: A Good Moment To Buy Shares In This Sterilization Leader
Summary Steris provides infection prevention products and sterilization services to medical clientele (such as hospitals, outpatient surgery centers, and pharmaceutical companies). Steris has increased its dividend for 21 consecutive years. The 10-year dividend growth rate of 9.6% is strong, but more recent dividend raises have actually been over 10%. STE has a great financial position. Its long-term debt/equity ratio is 0.3, while the interest coverage ratio is over 18. The P/E ratio is now down to 26.6. That’s far lower than its five-year average of 46.8. Read the full article on Seeking Alpha
내러티브 업데이트 • Jun 24
STE: Share Repurchases And Recurring Platform Earnings Will Support Future Upside
Analysts have made a small adjustment to their price target on STERIS, keeping fair value around $256.86 while fine-tuning assumptions on discount rate, revenue growth, profit margin and future P/E to reflect updated expectations for the business. What's in the News STERIS reported fiscal 2026 adjusted EPS of $10.17 compared with $9.22 a year earlier and total revenue of $5.94b, with broad-based revenue growth led by healthcare and faster percentage gains in Life Sciences.내러티브 업데이트 • Jun 04
STE: Share Repurchases And Earnings Outlook Will Support Future Upside
Analysts have trimmed their price target for STERIS to $256.86 from $279.29, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that collectively point to a lower fair value estimate. What's in the News STERIS announced a share repurchase program authorizing the company to buy back up to US$1,000 million of its ordinary shares.내러티브 업데이트 • May 11
STE: Lower Discount Rate And Stable Assumptions Will Support Future Upside
Analysts have maintained their $279.29 price target for STERIS, supported by a slightly lower discount rate and minor adjustments to long-term revenue growth, profit margin, and future P/E assumptions. Valuation Changes Fair Value: Maintained at $279.29 per share, with no change in the updated analysis.내러티브 업데이트 • Apr 26
STE: Share Repurchases And Stable Assumptions Will Support Future Upside
Analysts have reiterated a $279.29 price target for STERIS, citing largely unchanged assumptions on growth, margins, discount rate and future P/E as the basis for maintaining their current valuation framework. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of its shares under an existing buyback program (Key Developments).내러티브 업데이트 • Apr 11
STE: Completed Buyback And Stable Assumptions Will Support Future Upside
Analysts kept their fair value estimate for STERIS steady at about $279 per share, while slightly updating assumptions around discount rate, revenue growth, profit margin, and future P/E. This reflects fine tuning of their models rather than a shift in the core outlook.내러티브 업데이트 • Mar 28
STE: Completed Buyback And Refined Assumptions Will Support Future Upside
Analysts have reduced their price target on STERIS by about $2 to reflect slightly updated assumptions for fair value, discount rate, revenue growth, profit margin, and forward P/E, while maintaining the overall thesis. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, accounting for 0.2% of its shares.분석 기사 • Mar 24
Is There Now An Opportunity In STERIS plc (NYSE:STE)?
STERIS plc ( NYSE:STE ) received a lot of attention from a substantial price movement on the NYSE over the last few...내러티브 업데이트 • Mar 11
STE: Completed Share Repurchases And Stable Assumptions Will Support Future Upside
Analysts have kept their STERIS price target steady at $281.25, with only minor tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock's valuation. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of shares.내러티브 업데이트 • Feb 25
STE: Completed Share Repurchases And Steady Assumptions Will Support Future Upside
Analysts have slightly trimmed their fair value estimate for STERIS to about $281 from roughly $282, reflecting modest tweaks to assumptions on the discount rate, long term revenue growth, profit margin, and future P/E expectations. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of its shares.내러티브 업데이트 • Feb 10
STE: Modest Assumption Tweaks Will Support A More Upbeat Fair View
Analysts have slightly adjusted their price target for STERIS to US$281.63, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E. Together, these factors suggest a modest recalibration of expectations rather than a major shift in outlook.내러티브 업데이트 • Jan 27
STE: Share Repurchases And Stable Outlook Will Support A Fair View
Analysts have kept their fair value estimate for STERIS steady at about $281.63 per share, while making only very small tweaks to assumptions such as the discount rate and future P/E, reflecting largely unchanged views on the company’s long term earnings power. What's in the News From July 1, 2025 to September 30, 2025, STERIS repurchased 400,000 shares, representing 0.41% of its shares, for $98.64 million under its existing buyback program (Key Developments).내러티브 업데이트 • Jan 10
STE: Share Repurchases And Steady Guidance Will Support A Fair Outlook
Analysts have kept their fair value estimate for STERIS essentially unchanged at about US$281.63, citing only very small tweaks to assumptions such as the discount rate, revenue growth, profit margin and future P/E that do not materially affect their overall price target view. What's in the News STERIS repurchased 400,000 shares from July 1, 2025 to September 30, 2025, representing 0.41% of shares for US$98.64 million, as part of its ongoing buyback program.분석 기사 • Jan 09
Here's Why STERIS (NYSE:STE) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...분석 기사 • Dec 26
Earnings Tell The Story For STERIS plc (NYSE:STE)
With a price-to-earnings (or "P/E") ratio of 36.4x STERIS plc ( NYSE:STE ) may be sending very bearish signals at the...내러티브 업데이트 • Dec 23
STE: Share Repurchases And Steady Guidance Will Support A Fair Future Outlook
Analysts have modestly raised their price target on STERIS to $281.63, reflecting slightly higher long term growth and profitability expectations, despite largely unchanged model assumptions. What's in the News STERIS completed a share repurchase tranche between July 1 and September 30, 2025, buying back 400,000 shares, or 0.41% of shares outstanding, for $98.64 million (Key Developments).내러티브 업데이트 • Dec 09
STE: Modest Buybacks And Steady Guidance Will Support A Balanced Outlook
Analysts have modestly raised their price target on STERIS to approximately $282 per share from about $281.60, reflecting slightly lower perceived risk and a steady outlook for revenue growth, profit margins, and long term valuation multiples. What's in the News Completed a share repurchase program totaling 1,307,158 shares, or about 1.32% of shares outstanding, for $298.64 million under the buyback announced on May 3, 2023 (company filing).내러티브 업데이트 • Nov 25
STE: Stable Outlook And Share Buybacks Will Shape Near-Term Performance
Analysts have raised their price target for STERIS from $278.38 to $281.63. This change reflects modest expectations for improved revenue growth, even though there have been minor adjustments to other key financial metrics.내러티브 업데이트 • Nov 07
STE: Marginal Profit Margin Gains And Steady Outlook Will Influence Value
Analysts have raised their price target for STERIS from $272.38 to $278.38. They cite marginal improvements in projected profit margins, even though revenue growth expectations have been slightly reduced.분석 기사 • Oct 27
Is STERIS (NYSE:STE) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...내러티브 업데이트 • Sep 05
Healthcare Demand And Facility Expansion Will Create Value
With STERIS’s discount rate and future P/E both virtually unchanged, analyst valuation perspectives remain steady, resulting in an unchanged consensus price target of $272.38. What's in the News STERIS completed $200 million in share repurchases, totaling 907,158 shares (0.92%) under its current buyback program; no additional shares were repurchased in the latest quarter.분석 기사 • Aug 28
Calculating The Fair Value Of STERIS plc (NYSE:STE)
Key Insights STERIS' estimated fair value is US$227 based on 2 Stage Free Cash Flow to Equity With US$249 share price...분석 기사 • Aug 07
STERIS (NYSE:STE) Is Paying Out A Larger Dividend Than Last Year
The board of STERIS plc ( NYSE:STE ) has announced that it will be increasing its dividend by 11% on the 26th of...Seeking Alpha • Mar 22
Steris: AST Recovery Is Ongoing; Upgrading To 'Strong Buy'
Summary Upgraded Steris to 'strong buy' with a fair value of $254 per share due to strong recovery in its Applied Sterilization Technologies (AST) business. AST segment showed 9.5% organic growth, with management confident in further recovery despite challenges from rising labor costs and raw material inflation. For FY25, Steris guides for 6% revenue growth and 3.1% adjusted EPS growth, with significant contributions expected from Healthcare Products and AST segments. Key risks include weak capital equipment sales due to economic conditions, but overall, Steris's differentiated AST portfolio supports a positive long-term outlook. Read the full article on Seeking AlphaSeeking Alpha • Nov 18
Steris Q2: Anticipating HSD Growth In AST, Upgrade To 'Buy'
Summary I am upgrading STERIS to a 'Buy' with a fair value of $240 per share due to the recent stock price pullback and solid growth prospects. STERIS reported 7.2% organic revenue growth and 5.4% adjusted EPS growth, with strong performance in the Applied Sterilization Technologies segment. Despite high interest rates, I anticipate a gradual recovery in the biotech industry, driving future double-digit revenue growth in STERIS' AST business. Key risks include potential legal liabilities from EtO emissions and weak near-term growth in healthcare capital equipment revenue. Read the full article on Seeking AlphaSeeking Alpha • Sep 16
Steris: Dental Divestiture, Surgical Instrumentation Acquisition, But Overvalued
Summary I reiterate a 'Hold' rating for Steris stock with a fair value of $220 per share, citing strong healthcare growth and overvaluation concerns. The divestiture of the dental business and acquisition of Surgical Instrumentation assets will allow Steris to focus on core healthcare and AST businesses. Steris reported 5.4% organic revenue growth and 7% adjusted EPS growth, driven by a 7.2% increase in AST business and strong healthcare performance. Despite strategic moves, cautious outlook on healthcare capital equipment spending due to high-interest rates supports maintaining a 'Hold' rating. Read the full article on Seeking Alpha
새로운 내러티브 • Aug 20
Robust Revenue Growth And Expanding Margins In The Medical Equipment Sector
Strong start to the fiscal year and gross margin improvements suggest underappreciated growth momentum and potential for expanding net margins.Seeking Alpha • Aug 13
Steris: Q2 Numbers Solidify Buy Thesis
Summary STE's Q1 FY'25 numbers were in line with expectations, with upsides in the healthcare and AST divisions. The company shows consistent free cash flow production and stable earnings on its capital base. I've revised our estimate on the intrinsic worth of the business to $270 per share, reiterating a buy. Read the full article on Seeking Alpha매출 및 비용 세부 내역
매출 및 비용 세부 내역
STERIS가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 31 Mar 26 | 5,936 | 782 | 1,402 | 113 |
| 31 Dec 25 | 5,828 | 709 | 1,383 | 112 |
| 30 Sep 25 | 5,702 | 689 | 1,366 | 110 |
| 30 Jun 25 | 5,571 | 648 | 1,343 | 108 |
| 31 Mar 25 | 5,460 | 610 | 1,323 | 108 |
| 31 Dec 24 | 5,398 | 617 | 1,299 | 107 |
| 30 Sep 24 | 5,326 | 591 | 1,269 | 105 |
| 30 Jun 24 | 5,235 | 561 | 1,256 | 105 |
| 31 Mar 24 | 5,139 | 551 | 1,227 | 104 |
| 31 Dec 23 | 4,683 | 1,036 | 1,045 | 100 |
| 30 Sep 23 | 4,601 | 1,012 | 1,043 | 100 |
| 30 Jun 23 | 4,563 | 576 | 1,050 | 98 |
| 31 Mar 23 | 4,536 | 557 | 1,070 | 98 |
| 31 Dec 22 | 4,784 | -28 | 1,360 | 101 |
| 30 Sep 22 | 4,777 | -8 | 1,361 | 101 |
| 30 Jun 22 | 4,773 | 377 | 1,369 | 95 |
| 31 Mar 22 | 4,223 | 285 | 1,117 | 87 |
| 31 Dec 21 | 4,248 | 279 | 1,081 | 79 |
| 30 Sep 21 | 3,848 | 250 | 950 | 71 |
| 30 Jun 21 | 3,407 | 286 | 793 | 68 |
| 31 Mar 21 | 3,108 | 397 | 696 | 66 |
| 31 Dec 20 | 3,057 | 433 | 683 | 66 |
| 30 Sep 20 | 3,022 | 424 | 679 | 66 |
| 30 Jun 20 | 3,003 | 413 | 685 | 66 |
| 31 Mar 20 | 3,031 | 408 | 709 | 66 |
| 31 Dec 19 | 2,976 | 393 | 676 | 64 |
| 30 Sep 19 | 2,898 | 336 | 683 | 63 |
| 30 Jun 19 | 2,840 | 319 | 665 | 62 |
| 31 Mar 19 | 2,782 | 304 | 645 | 63 |
| 31 Dec 18 | 2,730 | 269 | 637 | 65 |
| 30 Sep 18 | 2,696 | 316 | 622 | 65 |
| 30 Jun 18 | 2,651 | 303 | 618 | 63 |
| 31 Mar 18 | 2,620 | 291 | 616 | 61 |
| 31 Dec 17 | 2,585 | 243 | 650 | 59 |
| 30 Sep 17 | 2,570 | 144 | 630 | 58 |
| 30 Jun 17 | 2,582 | 120 | 640 | 59 |
| 31 Mar 17 | 2,613 | 110 | 652 | 59 |
| 31 Dec 16 | 2,616 | 142 | 523 | 58 |
| 30 Sep 16 | 2,588 | 167 | 560 | 58 |
| 30 Jun 16 | 2,431 | 135 | 569 | 57 |
| 31 Mar 16 | 2,233 | 111 | 544 | 57 |
| 31 Dec 15 | 2,042 | 94 | 629 | 57 |
| 30 Sep 15 | 1,897 | 113 | 514 | 57 |
양질의 수익: STE는 고품질 수익을 보유하고 있습니다.
이익 마진 증가: STE의 현재 순 이익률 (13.2%)은 지난해 (11.2%)보다 높습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: STE의 수익은 지난 5년 동안 연평균 21.6%로 크게 증가했습니다.
성장 가속화: 지난 1년간 STE 의 수익 증가율(28.2%)은 연간 평균(21.6%)을 초과합니다.
수익 대 산업: STE의 지난 1년 수익 증가율(28.2%)은 Medical Equipment 업계의 13.7%를 상회했습니다.
자기자본이익률
높은 ROE: STE의 자본 수익률(10.9%)은 낮음으로 평가됩니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/31 04:49 |
| 종가 | 2026/07/31 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2026/03/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
STERIS plc는 17명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Michael Polark | Baird |
| Erin Wilson Wright | BofA Global Research |
| David Turkaly | Citizens JMP Securities, LLC |